Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3473329 in Adults With Elevated Lp(a) and High Cardiovascular Risk
CTR20230838Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of muvalaplin in hyperlipoproteinemia, dyslipidemia, atherosclerotic disease, sponsored by Eli Lilly and Company. Started Mar 2023; status: completed.
02
Drugs
muvalaplin
03
Conditions
hyperlipoproteinemiadyslipidemiaatherosclerotic disease
Beyond the preview
Go deeper on CTR20230838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230838.